Roche aquires HPV patent portfolio from Institut Pasteur
Roche Diagnostics and the Institut Pasteur (Pasteur) today announced that Pasteur has assigned a broad portfolio of patents pertaining to the Human Papillomavirus (HPV) to Roche for an undisclosed sum. As part of the transaction, Institut Pasteur has assigned to Roche its rights to all cross license agreements concerning other HPV patents owned by others. With these assignments, Roche now has access to one of the most extensive range of HPV subtypes in the diagnostic industry.
Scientists have identified more than 100 subtypes of HPV. Approximately one-third of HPV subtypes are spread through sexual contact, making it one of the most common sexually transmitted infections (STDs).
There is the potential for HPV molecular tests to be used as the primary screen for cervical cancer detection, replacing traditional Pap smear testing. In 2001, worldwide HPV molecular diagnostic sales were approximately US $21 million. The total market potential for HPV molecular tests, if adopted as a primary screening test, is estimated to exceed US $600 million annually by year 2010.
Source: Roche Diagnostics View latest company information
Posted: June 7, 2002
[will open your email client]